Suicidal Ideation

Suicide is the 10th leading cause of death in the United States, claiming approximately 49,000 lives annually. For every death by suicide, there are an estimated 25 attempted suicides and 275 people who seriously consider it. Suicidal ideation — persistent thoughts of ending one's life — is a psychiatric emergency that demands rapid intervention.

Traditional psychiatric treatments for suicidal ideation, including hospitalization, SSRIs, lithium, and psychotherapy, are critically important but share a significant limitation: they take time to work. SSRIs require weeks to months to achieve therapeutic effects, and there has been a critical gap in treatments that can rapidly reduce suicidal thoughts in acute situations.

Ketamine has been identified as one of the only pharmacological treatments capable of rapidly reducing suicidal ideation — often within hours rather than weeks. This rapid anti-suicidal effect is independent of its antidepressant action, suggesting a distinct mechanism that makes it uniquely valuable for this most urgent of psychiatric indications.

Ketamine's rapid anti-suicidal effects appear to operate through several distinct mechanisms:

• Rapid neuroplasticity: Suicidal ideation is associated with rigid, hopeless thinking patterns tied to prefrontal cortex dysfunction and loss of synaptic connections. Ketamine's rapid synaptogenesis may restore the neural flexibility needed to envision alternatives and generate hope.
• Anti-anhedonic effects: Anhedonia (the inability to feel pleasure) is one of the strongest predictors of suicidal behavior. Ketamine rapidly reverses anhedonia in many patients, restoring the ability to experience positive emotions and motivation.
• Opioid system modulation: Research suggests ketamine's anti-suicidal effects may partially involve the endogenous opioid system, which plays a role in emotional pain processing and social bonding.
• Inflammation reduction: Elevated inflammatory markers are consistently found in suicidal patients. Ketamine's anti-inflammatory properties may contribute to its rapid anti-suicidal effects.
• Glutamate homeostasis: Suicidality has been linked to glutamatergic dysfunction, and ketamine's NMDA antagonism may help restore glutamate homeostasis in circuits involved in emotional regulation and decision-making.

Treatment of suicidal ideation with ketamine requires careful clinical protocols:

• Emergency setting: Ketamine for acute suicidal ideation may be administered in emergency departments, psychiatric inpatient units, or specialized ketamine clinics with appropriate safety protocols.
• Spravato (esketamine): In 2020, Spravato received FDA approval for the indication of treatment-resistant depression with acute suicidal ideation or behavior (MDSI), making it the first drug specifically approved to address acute suicidality.
• Monitoring: Patients receiving ketamine for suicidal ideation require close psychiatric monitoring during and after treatment, including suicide risk assessment before, during, and after each session.
• Integration with safety planning: Ketamine should be administered as part of a comprehensive suicide prevention strategy that includes safety planning, psychotherapy, family involvement, and ongoing psychiatric care.
• Induction and maintenance: Acute reduction of suicidal ideation may be achieved with 1–3 infusions, followed by a standard induction series and maintenance protocol for the underlying mood disorder.

Treating suicidal patients with ketamine requires additional safety measures:

• Psychiatric expertise: Treatment should involve clinicians experienced in suicide risk assessment and management, not just ketamine administration.
• Comprehensive evaluation: Thorough assessment of suicide risk factors, protective factors, access to means, and psychosocial stressors is essential before, during, and after treatment.
• Post-infusion monitoring: Extended observation periods may be appropriate for acutely suicidal patients. Discharge planning should include safety plans and follow-up appointments.
• Not a standalone treatment: Ketamine should never be used as the sole intervention for suicidal ideation. It must be part of a comprehensive treatment plan including ongoing psychiatric care, psychotherapy, and social support.
• Standard medical precautions: All standard ketamine safety protocols apply, including cardiovascular monitoring and assessment of contraindications.